Transparency Market Research in its new report titled, “Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the gastroenteropancreatic neuroendocrine tumor therapeutics market. The TMR report anticipates that the increase in geriatric population and rise in prevalence of colorectal cancer will drive the gastroenteropancreatic neuroendocrine tumor therapeutics market during the forecast period i.e, 2018-2026. However, side effects associated with drugs such as nausea, vomiting, and long treatment procedures are likely to restrain the market in the next few years, says the report.
The TMR report has segregated the gastroenteropancreatic neuroendocrine tumor therapeutics market based on therapy, drug, and region. In terms of therapy, the global gastroenteropancreatic neuroendocrine tumor therapeutics market is categorized into chemotherapy, peptide-receptor radionuclide therapy, and others. Among these, the chemotherapy segment is likely to grow at a rapid pace during the forecast period because the patient’s recovery response rate through chemotherapy treatment is high as compared to other therapies. Moreover, chemotherapy is well tolerated, with minimal side effects such as nausea, and abdominal pain. On the basis of drug, the global treatment market is classified into lutathera, sunitinib, everolimus, and others. Among these, the lutathera segment is anticipated to grow at a rapid pace during the forecast period because lutathera is a radiolabeled molecule that binds to the specific receptors of the tumor and stop its growth in a short time as compared to other drugs.
On a geographical perspective, the global gastroenteropancreatic neuroendocrine tumor therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to the report, North America dominates the global market and the same pattern is expected to follow. The region is projected to account for a significant share of the global market during the forecast period, due to rise in prevalence of small intestine cancer and colorectal cancer. According to the American Cancer Society, more than 10,000 people were effected with some type of small intestine cancer in 2017. Increase in the geriatric population and favorable reimbursement policy for the treatment of gastroenteropancreatic neuroendocrine tumors are projected to drive the market in Europe. Rise in prevalence of digestive cancer and increase in awareness about screening test to detect early tumors or cancer are anticipated to propel the market in Asia Pacific during the forecast period. Surge in awareness about the harmful effects of gastroenteropancreatic neuroendocrine tumors and high diagnosis rates are likely to augment the gastroenteropancreatic neuroendocrine tumors therapeutics market in Middle East & Africa during the forecast period.
Some of the major players operating in the global gastroenteropancreatic neuroendocrine tumor therapeutics market are profiled in this report to give a better competitive analysis of the market and these include Novartis, Pfizer, Inc., Fresenius Kabi, Teva Pharmaceutical, and Sun Pharma, among others.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]